Comparison of Modular PEG Incorporation Strategies for Stabilization of Peptide–siRNA Nanocomplexes (2016)
Transportan–LyP-1 (tandem peptide)
Sequence: myr-GGWTLNSAGYLLGKINLKALAALAKKIL-GGGG-CGNKRTRGC
| Experiment Id | EXP002560 |
|---|---|
| Paper | Comparison of Modular PEG Incorporation Strategies for Stabilization of Peptide–siRNA Nanocomplexes |
| Peptide | Transportan–LyP-1 (tandem peptide) |
| Delivery Success Class | no |
| In Vivo Flag | yes |
| Uptake Confirmed | yes |
| Label Confidence | high |
| In Vitro Functional Effect | |
| Endosomal Escape Evidence | |
| Peptide Concentration | 0.5 nmol siRNA per mouse |
| Rna Concentration | 0.5 nmol per dose |
| Mixing Ratio | 15:15:1 peptide:PEG:siRNA |
| Formulation Format | Tumor-penetrating nanocomplex (TPN) |
| Formulation Components | Tandem peptide + siRNA ± PEGylated peptide / PEG lipid / PEG graft polymer |
| Size Nm | 100.00 |
| Zeta Mv | 10.00 |
| Model Scope | in_vivo |
| Model Type | in vivo |
| Cell Lines Or Primary Cells | |
| Animal Model | MDA-MB-435 xenograft mouse model |
| Administration Route | Intravenous (tail vein) |
| Output Type | Circulation time and biodistribution |
| Output Value | Improved blood circulation; reduced lung, liver, spleen accumulation |
| Output Units | |
| Output Notes | No therapeutic endpoint measured |
| Toxicity Notes | No complement activation detected |
| Curation Notes |